SEC Form 4 · accession 0001209191-17-019952
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
G Bradley Cole
Officer — COO
Period of report
Mar 8, 2017
Accepted (ET)
Mar 10, 2017 · 6:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 8, 2017 | M | 5,610 | $23.31 | A | 45,338 | D | |
| Common StockF2,F3,F4,F1 | Mar 8, 2017 | S | 5,610 | $31.5778 | D | 39,728 | D | |
| Common StockF1 | Mar 8, 2017 | M | 100 | $23.31 | D | 39,628 | D | |
| Common StockF2,F5,F1 | Mar 8, 2017 | S | 100 | $29.83 | D | 39,528 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $23.31 | Mar 8, 2017 | M | 100 | D | — | Dec 6, 2017 | Common Stock | 0 | 5,610 | D |
| Employee Stock Option (right to buy)F6 | $23.31 | Mar 8, 2017 | M | 5,610 | D | — | Dec 6, 2017 | Common Stock | 0 | 0 | D |
Explanation of responses
- F1Includes an aggregate of 18,174 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 8, 2016.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $31.41 to $31.88.
- F5Represents actual sale price.
- F6The option became exercisable as to 25% of the shares on December 6, 2008, and became exercisable as to 1/48th of the shares each full month thereafter.